Literature DB >> 11134369

Selegiline and Parkinson's disease: it's déjà vu-again.

J W Langston, C M Tanner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11134369     DOI： 10.1212/wnl.55.12.1770

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

Review 1.  The genetic basis of Parkinson's disease.

Authors:  T Foltynie; S Sawcer; C Brayne; R A Barker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

2.  Piecing together the puzzle of progression and mortality in Parkinson's disease.

Authors:  Connie Marras; David Oakes
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

Review 3.  Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.

Authors:  G W Ross; H Petrovitch
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats.

Authors:  Sara A Wahdan; Mariane G Tadros; Amani E Khalifa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-23       Impact factor: 3.000

Review 5.  Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Authors:  M Jyothi Kumar; Julie K Andersen
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.